This is a multiple part, multiple cohort study evaluating single and multiple ascending doses, relative bioavailability, food effect, and drug-drug interaction of NX-5948 in healthy volunteers.
Age range
19 Years – 55 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Area under the concentration-time curve from time 0 to last observed non-zero concentration (AUC0-t): NX-5948
Timeframe: 9 weeks
Area under the concentration-time curve from time 0 extrapolated to infinity (AUC0-inf): NX-5948
Timeframe: 9 weeks
Maximum observed concentration (Cmax): NX-5948
Timeframe: 9 weeks
AUC0-t: Midazolam, rosuvastatin, or digoxin
Timeframe: 9 weeks
AUC0-inf: Midazolam, rosuvastatin, or digoxin
Timeframe: 9 weeks
Cmax: Midazolam, rosuvastatin, or digoxin
Timeframe: 9 weeks
Placebo-corrected change from baseline QT interval (QTc) as measured by electrocardiogram
Timeframe: Baseline, 9 weeks
Number of participants with treatment-emergent adverse events
Timeframe: Up to 10 weeks